BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35022913)

  • 1. Ursolic acid as a potential inhibitor of Mycobacterium tuberculosis cytochrome bc1 oxidase-a molecular modelling perspective.
    Tembe N; Machaba KE; Ndagi U; Kumalo HM; Mhlongo NN
    J Mol Model; 2022 Jan; 28(2):35. PubMed ID: 35022913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
    Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
    mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis.
    Lupien A; Foo CS; Savina S; Vocat A; Piton J; Monakhova N; Benjak A; Lamprecht DA; Steyn AJC; Pethe K; Makarov VA; Cole ST
    PLoS Pathog; 2020 Jan; 16(1):e1008270. PubMed ID: 31971990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refined homology model of cytochrome bcc complex B subunit for virtual screening of potential anti-tuberculosis agents.
    Pan Z; Wang Y; Gu X; Wang J; Cheng M
    J Biomol Struct Dyn; 2020 Oct; 38(16):4733-4745. PubMed ID: 31674290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13.
    Cruz JN; Costa JFS; Khayat AS; Kuca K; Barros CAL; Neto AMJC
    J Biomol Struct Dyn; 2019 Apr; 37(6):1616-1627. PubMed ID: 29633908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of protein-ligand binding motions through protein conformational morphing and clustering of cytochrome bc1-aa3 super complex.
    Sindhu T; Rajamanikandan S; Jeyakanthan J; Pal D
    J Mol Graph Model; 2023 Jan; 118():108347. PubMed ID: 36208591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 4-Amino-Thieno[2,3-
    Harrison GA; Mayer Bridwell AE; Singh M; Jayaraman K; Weiss LA; Kinsella RL; Aneke JS; Flentie K; Schene ME; Gaggioli M; Solomon SD; Wildman SA; Meyers MJ; Stallings CL
    mSphere; 2019 Sep; 4(5):. PubMed ID: 31511370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
    Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
    J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
    Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
    Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursolic acid and carvacrol may be potential inhibitors of dormancy protein small heat shock protein16.3 of Mycobacterium tuberculosis.
    Jee B; Kumar S; Yadav R; Singh Y; Kumar A; Sharma N
    J Biomol Struct Dyn; 2018 Oct; 36(13):3434-3443. PubMed ID: 28984500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative modeling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis.
    Fakhar Z; Naiker S; Alves CN; Govender T; Maguire GE; Lameira J; Lamichhane G; Kruger HG; Honarparvar B
    J Biomol Struct Dyn; 2016 Nov; 34(11):2399-417. PubMed ID: 26612108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative modeling and dynamic simulation of UDP-N-acetylmuramoyl-alanine ligase (MurC) from Mycobacterium tuberculosis through virtual screening and toxicity analysis.
    Isa MA
    Life Sci; 2020 Dec; 262():118466. PubMed ID: 32961233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.
    Chandrasekera NS; Berube BJ; Shetye G; Chettiar S; O'Malley T; Manning A; Flint L; Awasthi D; Ioerger TR; Sacchettini J; Masquelin T; Hipskind PA; Odingo J; Parish T
    ACS Infect Dis; 2017 Dec; 3(12):898-916. PubMed ID: 29035551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations.
    Kamsri P; Punkvang A; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
    SAR QSAR Environ Res; 2019 Nov; 30(11):775-800. PubMed ID: 31607177
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug targeted virtual screening and molecular dynamics of LipU protein of Mycobacterium tuberculosis and Mycobacterium leprae.
    Kaur G; Pandey B; Kumar A; Garewal N; Grover A; Kaur J
    J Biomol Struct Dyn; 2019 Mar; 37(5):1254-1269. PubMed ID: 29557724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular docking, molecular dynamics simulations and binding free energy studies of interactions between Mycobacterium tuberculosis Pks13, PknG and bioactive constituents of extremophilic bacteria.
    Nyambo K; Tapfuma KI; Adu-Amankwaah F; Julius L; Baatjies L; Niang IS; Smith L; Govender KK; Ngxande M; Watson DJ; Wiesner L; Mavumengwana V
    Sci Rep; 2024 Mar; 14(1):6794. PubMed ID: 38514663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel and potent InhA inhibitors by an
    Hanwarinroj C; Phusi N; Kamsri B; Kamsri P; Punkvang A; Ketrat S; Saparpakorn P; Hannongbua S; Suttisintong K; Kittakoop P; Spencer J; Mulholland AJ; Pungpo P
    Future Med Chem; 2022 May; 14(10):717-729. PubMed ID: 35485258
    [No Abstract]   [Full Text] [Related]  

  • 18. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the
    Ezquerra-Aznárez JM; Degiacomi G; Gašparovič H; Stelitano G; Sammartino JC; Korduláková J; Governa P; Manetti F; Pasca MR; Chiarelli LR; Ramón-García S
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
    Khan AM; Shawon J; Halim MA
    J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the structure of Mycobacterium tuberculosis MbtA: model validation using molecular dynamics simulations and docking studies.
    Maganti L; Open Source Drug Discovery Consortium ; Ghoshal N
    J Biomol Struct Dyn; 2014; 32(2):273-88. PubMed ID: 23527569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.